STK33 kinase inhibitor BRD-8899 has no effect on KRAS-dependent cancer cell viability

STK33 kinase inhibitor BRD-8899 has no effect on KRAS-dependent cancer cell viability

Approximately 30% of human cancers harbor oncogenic gain-of-function mutations in KRAS. Despite interest in KRAS as a therapeutic target, direct blockade of KRAS function with small molecules has yet to be demonstrated. Based on experiments that lower mRNA levels of protein kinases, KRAS-dependent c...

Full description

Bibliographic Details
Main Authors: Luo, Tuoping, Masson, Kristina, Jaffe, Jacob D., Silkworth, Whitney, Lee, Nathan Ross, Scherer, Christina A., Scholl, Claudia, Frohling, Stefan, Stern, Andrew M., Schreiber, Stuart L., Golub, Todd R., Carr, Steven A
Other Authors: Massachusetts Institute of Technology. Engineering Systems Division
Format: Article
Language:en_US
Published: National Academy of Sciences 2012
Online Access:http://hdl.handle.net/1721.1/72564
https://orcid.org/0000-0002-7203-4299

Similar Items

Similar Items